XARELTO® (rivaroxaban) Reduces Recurrent Blood Clots and Total Medical Costs in Morbidly Obese Patients - BioSpace

XARELTO® (rivaroxaban) Reduces Recurrent Blood Clots and Total Medical Costs in Morbidly Obese Patients  BioSpace

TITUSVILLE, N.J., Sept. 20, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today important new real-world ...



Comments

Popular posts from this blog

Anand Swaminath, MD, Discusses Rationale for Assessing SBRT Vs CRT in Central/Peripheral NSCLC - Cancer Network